Michael Freeman
Stock Analyst at Raymond James
(2.08)
# 3,015
Out of 5,246 analysts
6
Total ratings
60%
Success rate
5.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Freeman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Assumes: Outperform | $14 | $6.38 | +119.44% | 1 | Jun 11, 2025 | |
| TECX Tectonic Therapeutic | Reinstates: Outperform | $76 | $29.09 | +161.26% | 1 | Jun 11, 2025 | |
| DYN Dyne Therapeutics | Assumes: Outperform | $37 | $17.37 | +113.01% | 1 | Jun 11, 2025 | |
| IRON Disc Medicine | Reinstates: Strong Buy | $89 | $66.82 | +33.19% | 1 | Jun 11, 2025 | |
| RNA Atrium Therapeutics | Initiates: Strong Buy | $65 | $13.07 | +397.32% | 1 | Jun 11, 2025 | |
| BHC Bausch Health Companies | Initiates: Market Perform | $8 | $5.47 | +46.25% | 1 | Jul 10, 2024 |
Wave Life Sciences
Jun 11, 2025
Assumes: Outperform
Price Target: $14
Current: $6.38
Upside: +119.44%
Tectonic Therapeutic
Jun 11, 2025
Reinstates: Outperform
Price Target: $76
Current: $29.09
Upside: +161.26%
Dyne Therapeutics
Jun 11, 2025
Assumes: Outperform
Price Target: $37
Current: $17.37
Upside: +113.01%
Disc Medicine
Jun 11, 2025
Reinstates: Strong Buy
Price Target: $89
Current: $66.82
Upside: +33.19%
Atrium Therapeutics
Jun 11, 2025
Initiates: Strong Buy
Price Target: $65
Current: $13.07
Upside: +397.32%
Bausch Health Companies
Jul 10, 2024
Initiates: Market Perform
Price Target: $8
Current: $5.47
Upside: +46.25%